SCHEDULE: Sunshine Biopharma: Ownership Threshold Update

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, have filed an amended Schedule 13G, reporting beneficial ownership of 9.99% of Sunshine Biopharma Inc. common stock.

Summary

• The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting for Sunshine Biopharma Inc.
• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC are the reporting persons.
• As of June 30, 2026, the reporting persons collectively hold 235,697 shares of common stock, representing 9.99% of the outstanding shares.
• This ownership is primarily derived from the exercise of a warrant held by Intracoastal Capital LLC, referred to as 'Intracoastal Warrant 1'.
• The reported ownership is subject to 'blocker provisions' in the warrants, which limit exercise to prevent beneficial ownership exceeding 9.99% for Warrant 1 and 4.99% for a second warrant ('Intracoastal Warrant 2').
• Without these blocker provisions, the reporting persons could potentially beneficially own 2,197,321 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports on existing beneficial ownership thresholds rather than new strategic developments or significant changes in holdings.

Positives

• The reporting persons maintain a significant ownership stake, indicating continued interest in Sunshine Biopharma Inc.
• The existence of blocker provisions suggests a strategic approach to managing ownership levels and regulatory compliance.

Negatives

• The filing does not indicate any new investment or strategic initiative, but rather a reporting of existing beneficial ownership.
• The blocker provisions limit the immediate exercise of warrants, capping the potential ownership at 9.99% for Warrant 1 and 4.99% for Warrant 2, thus restricting further immediate stake increases through these instruments.

Risks

• The blocker provisions in the warrants could limit the reporting persons' ability to increase their stake in Sunshine Biopharma Inc. if market conditions or company performance warrant it.
• Future changes in ownership percentages could be influenced by the terms and limitations of the existing warrants.

Future Outlook

The filing does not contain specific forward-looking statements or guidance. It primarily reports on current beneficial ownership levels and the limitations imposed by warrant agreements.

Management Comments

• The reporting persons certify that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders who acquire more than 5% of a company's stock. This filing indicates a substantial, but capped, ownership position by Intracoastal Capital LLC and associated individuals in Sunshine Biopharma, a biotechnology company.

Stakeholder Impact

• Shareholders: The filing confirms a significant ownership block, which could influence market perception and trading dynamics, though the capped ownership limits immediate aggressive accumulation.
• Management: The reporting persons' certification regarding control implies a non-activist stance, which may be reassuring to current management.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Sunshine Biopharma Inc.
• Future actions may depend on the terms of the warrants and any changes in the company's stock performance or strategic direction.

Key Dates

Keywords

Sunshine Biopharma, Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Warrant Exercise, Ownership Threshold, Blocker Provision